A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis

References

• Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group: Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of randomized trials. Lancet. 2015;386:1341–1352.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005;23:1616–1622.
   PubMed Web of Science ®Google Scholar
• Frasor J, Danes JM, Komm B, et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinol. 2003;144:4562–4574.
   PubMed Web of Science ®Google Scholar
• Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole with tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. JCO. 2007;25:3846–3852.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Yochmowitz MG, Knight WA, III, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46:2884–2888.
   PubMed Web of Science ®Google Scholar
• Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973–1979.
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. JCO. 2003;21:2101–2109.
   PubMed Web of Science ®Google Scholar
• Henriksen KL, Rasmussen BB, Lykkesfeldt AE, et al. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009;48:522–531.
   PubMed Web of Science ®Google Scholar
• Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estrogen and antiestrogen. Endocrinol. 1978;15:14–19.
   Google Scholar
• Dong LA, Wang WL, Wang F, et al. Mechanisms of transcriptional activation of bcl-2 gene expression by 17 beta-oestradiol in breast cancer cells. J Biol Chem. 1999;264:32099–32107.
   Web of Science ®Google Scholar
• Stewart AJ, Johnson MD, May FE, et al. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem. 1990;265:21172–21178.
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757.
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–776.
   PubMed Web of Science ®Google Scholar
• Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12:1101–1108.
   PubMed Web of Science ®Google Scholar
• Henriksen KL, Rasmussen BB, Lykkesfeldt AE, et al. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol. 2007;60:397–404.
   PubMed Web of Science ®Google Scholar
• Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–168.
   PubMed Web of Science ®Google Scholar
• Olsen KE, Knudsen H, Rasmussen BB, Danish Breast Cancer Co-operative Group, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 2004;43:35–42.
   PubMed Web of Science ®Google Scholar
• Larsen MS, Bjerre K, Lykkesfeldt AE, et al. Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. Breast. 2012;21:662–668.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Jensen MB, Mouridsen HT. Danish Breast Cancer Cooperative Group: Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol. 2014;53:174–185.
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann. Oncol. 2012;23:2866–2873.
   PubMed Web of Science ®Google Scholar
• Van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–729.
   PubMed Web of Science ®Google Scholar
• Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17:6012–6020.
   PubMed Web of Science ®Google Scholar
• Dubsky P, Brase JC, Jakesz R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer. 2013;109:2959–2964.
   PubMed Web of Science ®Google Scholar
• Giobbie-Hurder A, Price KN, Gelber RD. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials. 2009;6:272–287.
   PubMed Web of Science ®Google Scholar